EIKEN CHEMICAL CO.,LTD. (4549) Stock Price

Eiken Chemical is a company primarily engaged in the manufacturing and sale of diagnostic reagents. The company operates through two consolidated subsidiaries: Eiken Bioscience Technology (China) Limited and EIKEN MEDICAL AMERICA INC., and also includes one affiliate accounted for using the equity method, forming a corporate group.

Eiken Bioscience Technology (China) Limited primarily conducts contract manufacturing of diagnostic reagents for Eiken Chemical and the purchase, manufacturing, and sale of diagnostic reagents. This subsidiary handles the company's product supply to the Chinese market.

EIKEN MEDICAL AMERICA INC., by contrast, has not yet commenced operations. This subsidiary was established with a view to future expansion into the American market.

Eiken Chemical's business is primarily specialized in providing diagnostic reagents in the medical field, with an aim toward global expansion. Through this strategy, the company is strengthening its competitive position in international markets.

Eiken Chemical has established the "EIKEN ROAD MAP 2030" with the goal of achieving sustainable growth by 2030. The plan emphasizes enhancing employee capabilities and creating new possibilities through team-based challenges. The company also aims to drive innovation in medical processes and shape the future of diagnostic testing.

The company has identified three priority areas: cancer prevention and treatment, infectious disease elimination and control, and healthcare products and services. In oncology, the company is expanding into areas directly linked to treatment. In infectious diseases, it is focusing on establishing simple testing technologies. In healthcare, it is expanding products for telemedicine and home-based testing to improve quality of life.

The medium-term management plan adopts "Challenges to Innovation" as its slogan while strengthening the revenue base. Core strategies include developing overseas markets, restructuring the product portfolio, and developing new products to achieve sustained growth. The company is particularly focused on expanding overseas sales of fecal occult blood test reagents and increasing adoption of tuberculosis diagnostic systems.

As a financial strategy, the company is introducing ROIC to quantify profitability and capital efficiency, aiming to enhance corporate value. It is also promoting strategic investments in growth areas and strengthening shareholder returns. The company is strengthening governance through management structure reforms and the advancement of sustainability initiatives.